Not Yet RecruitingNCT06580873
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
Medication studyAges 18+CanadaAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- ReginaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: September 30, 2024
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Saskatchewan Health Authority - Regina Area
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT06580873
- Official title
Show the full official title
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Regina
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Saskatchewan Health Authority - Regina Area.
Does this study involve medication?
Yes. The study involves medication, including DOVATO.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
